HER-2 pulsed DC1
/ University of Pennsylvania, H. Lee Moffitt Cancer Center and Research Institute, ImmunoRestoration
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
September 25, 2025
NATASHA: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
(clinicaltrials.gov)
- P2 | N=53 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Oct 2025 ➔ Sep 2026
Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2
March 03, 2025
NATASHA: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
(clinicaltrials.gov)
- P2 | N=53 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Jan 2025 ➔ Oct 2026 | Trial primary completion date: Jan 2025 ➔ Oct 2025
Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2
February 16, 2024
NATASHA: Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
(clinicaltrials.gov)
- P2 | N=53 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Oct 2025 ➔ Jan 2025 | Trial primary completion date: Oct 2024 ➔ Jan 2025
Trial completion date • Trial primary completion date • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2
April 24, 2023
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
(clinicaltrials.gov)
- P2 | N=53 | Recruiting | Sponsor: H. Lee Moffitt Cancer Center and Research Institute | N=34 ➔ 53
Enrollment change • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2
1 to 4
Of
4
Go to page
1